IPT 001 - HERVOLUTION Therapeutics
Alternative Names: IPT-001 - HERVOLUTION TherapeuticsLatest Information Update: 06 Mar 2026
At a glance
- Originator HERVOLUTION Therapeutics
- Class Antineoplastics; Cancer vaccines; Immunotherapies; Virus-like particle vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Non-alcoholic steatohepatitis; Non-small cell lung cancer; Prediabetic state; Solid tumours
Most Recent Events
- 06 Mar 2026 Preclinical trials in Non-small cell lung cancer in Denmark (Parenteral) prior to March 2026 (HERVOLUTION Therapeutics pipeline, March 2026)
- 14 Jul 2025 Preclinical trials in Non-alcoholic steatohepatitis in Denmark (Parenteral) (HERVOLUTION Therapeutics pipeline, July 2025)
- 14 Jul 2025 Preclinical trials in Prediabetic state in Denmark (Parenteral) (HERVOLUTION Therapeutics pipeline, July 2025)